Grants for Public housing authorities - Health

The purpose of this Notice of Funding Opportunity (NOFO) is to support the development and validation of reagents/tools to support research to characterize cellular and molecular constituents of the bat immune system and for the study of protective innate and adaptive immune mechanisms in bats. The Research Resource Program established by this NOFO will participate within a collaborative research network to advance understanding of the bat immune response. This NOFO will support the establishment and operation of a Bat Immunology Research Resource Program for the development and validation of reagents/tools for use in immunological studies using the bat model system. The recipient will participate in the Bat Immunology Network, which will consist of the Research Resource Program, the research projects supported by RFA-AI-23-068, and possible other participants as determined by NIAID. The Research Resource Program will conduct reagent/tool development and validation using appropriate systems, which includes testing against multiple bat species. While other members of the Bat Immunology Network may assist in validation efforts, reagent/tool validation is the responsibility of the Research Resource Program. Reagents/tools developed by the Research Resource Program will be provided to the research projects of the Bat Immunology Network. Reagents/tools will be made available to the broader research community through technology transfer arrangements, deposition to nonprofit repositories, and/or timely transfer to industry for commercialization. Areas of high priority include, but are not limited to, the development and validation of the following: Soluble immune molecules (e.g., cytokines, chemokines) for use in tissue culture or in vivo animal studies Antibodies or other probes/detection markers for use in cellular phenotyping, functional studies and/or immunoassays

This funding opportunity supports innovative research aimed at developing new strategies for curing HIV at the start of antiretroviral therapy, targeting researchers and institutions focused on reducing the HIV reservoir and improving immune responses.

This FOA invites applications that propose research projects that test promising digital healthcare interventions aimed at improving quality of care and healthcare services delivery at the point of care. This FOA will use the Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities, and up to 3 years of R33 support for expanded activities.The Agency for Healthcare Research and Quality's (AHRQ) mission is to produce evidence to make health care safer, of higher quality, more accessible, equitable, and affordable, and to work within the U.S. Department of Health and Human Services and with other partners to make sure that the evidence is understood and used. This FOA invites applications that propose research projects that test promising digital healthcare interventions aimed at improving quality of care and healthcare services delivery at the point of care. This FOA will use the Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities, and up to 3 years of R33 support for expanded activities. Transition to the R33 phase is not guaranteed for all grants awarded under this FOA. Continuation from the R21 phase to the R33 phase will be determined by AHRQ staff based on progress achieved in the R21 phase and factors such as program priorities and availability of funds.

The National Eye Institute (NEI) supports investigator-initiated, complex, multi-center and other high resource risk epidemiologic studies under the cooperative agreement mechanism, UG1 activity code. Specifically, the purpose of this Funding Opportunity Announcement (FOA) is to support new and innovative ocular epidemiology research.The purpose of this Funding Opportunity Announcement (FOA) is to support epidemiologic studies that utilize creative and innovative approaches to studying vision diseases and disorders with high public impact and whose findings will inform prevention and treatment strategies as well as basic sciences research. Background: Clinical vision research projects, including epidemiologic studies, are part of NEI’s core strategy for improving visual health and decreasing visual impairment in populations through research on the burden of disease, its causes, diagnosis, prevention, treatment and rehabilitation. Projects should focus on NEI’s mission to protect and improve visual health including, but not limited to: Determining the burden of eye diseases and their visual outcomes in a changing population, particularly disparities in the burden and the influences of sociocultural, environmental, economic, and demographic factors. Improving early diagnosis of ocular diseases and their underlying processes through new screening and detection strategies. Determining risk factors for ocular diseases. Identifying and assessing strategies that will overcome barriers to eye care and convert evidence-based findings into improved patient and population outcomes. Studying the interplay of factors that exacerbate or mitigate risk for eye diseases. The NEI encourages applications to support ocular epidemiologic research. These projects are supported under the cooperative agreement mechanism. Applicants are strongly encouraged to contact Scientific/Research staff as plans for an application are being developed (see Section VII, Agency Contacts), preferably no later than 12 weeks prior to the anticipated application submission date.

The "Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research" grant aims to fund exploratory research projects that focus on the development of innovative technologies for analyzing molecular or cellular aspects of cancer, with the goal of improving cancer biology research, early detection, diagnosis, treatment, control, epidemiology, and addressing health disparities related to cancer.

This funding opportunity provides financial support to organizations working to improve laboratory diagnostics and monitoring for HIV/AIDS care and treatment in Jamaica and Trinidad and Tobago, enhancing public health outcomes in the Caribbean.

The National Institutes of Health (NIH) has announced a funding opportunity titled Co-infection and Cancer (R01 Clinical Trial Not Allowed) under Funding Opportunity Number PAR-25-082. This initiative, led by the National Cancer Institute (NCI), is aimed at advancing research into the roles of co-infection in cancer development and progression. Co-infection is defined as the occurrence of two or more infections, whether simultaneous or sequential, involving pathogens or non-pathogenic agents, including viruses, bacteria, and parasites. The goal of this program is to explore how these co-infections contribute to cancer risk and progression and identify potential strategies for cancer prevention and treatment. The program encourages investigations that focus on co-infections with known oncogenic agents, excluding human immunodeficiency virus (HIV), and seeks studies that can lead to new opportunities in cancer treatment and prevention. In addition to pathogenic agents, research that includes the role of non-pathogenic agents, such as those in the microbiome, will be considered responsive. The program supports projects that delve into uncharted areas of co-infection and cancer, with an emphasis on mechanistic and epidemiologic research that could have practical implications for cancer control. Applicants are encouraged to focus on differences in cancer susceptibility, progression, and survival among diverse populations, including those that are racially or ethnically diverse, as well as medically underserved communities. International collaborations are also supported, particularly for studies in low- and middle-income countries where infection-associated cancers are more prevalent. The first submission date is January 5, 2025, with application due dates beginning on February 5, 2025. Budgets are not limited but must align with the scope of the project, and the maximum project period is five years. Applications must be submitted electronically through NIH's ASSIST system or Grants.gov. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, and foreign entities. The program seeks to support well-developed research projects backed by preliminary data. Studies that focus solely on co-infection with HIV or involve only a single pathogen will not be considered responsive. Evaluation criteria include the scientific merit of the project, innovation, and feasibility, as well as the expertise of the research team. This funding opportunity offers a unique chance to explore how co-infections contribute to cancer and potentially uncover new strategies for prevention and treatment across diverse populations.

This funding opportunity supports research that provides critical data to help the FDA regulate tobacco products, targeting a wide range of organizations, including nonprofits, educational institutions, and community groups, to improve public health outcomes related to tobacco use.

This funding opportunity supports innovative researchers in the U.S. who are tackling significant challenges in diabetes, metabolic diseases, digestive disorders, and nutrition, with the goal of advancing groundbreaking scientific understanding and treatment.

This funding opportunity supports postdoctoral researchers from underrepresented groups in cancer research as they transition to independent faculty positions, providing salary and research funding to help establish their own research programs.

This funding opportunity supports innovative clinical research to explore the brain mechanisms behind substance use disorders, targeting a wide range of researchers and institutions dedicated to addressing addiction challenges.

The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA's current portfolio that has the potential to transform SUD research. The proposed research should: 1. develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research; and /or 2. test an innovative and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would transform current thinking.

This funding opportunity provides financial support for researchers to analyze and integrate existing data to better understand cancer risk, prevention, and treatment outcomes, particularly focusing on innovative methodologies and addressing health disparities.

This funding opportunity supports multidisciplinary research aimed at improving the understanding and treatment of asthma and allergic diseases, inviting applications from various institutions and organizations involved in clinical and translational research.

This funding opportunity supports innovative research projects that explore how T-cells contribute to HIV infection and related brain complications, targeting researchers from various institutions and organizations.

This funding opportunity supports innovative educational projects that engage K-12 students and teachers in the biomedical and behavioral sciences, particularly targeting individuals from diverse and underrepresented backgrounds.

The purpose of the Paul Calabresi Career Development Award for Clinical Oncology (PCACO) is to increase the number of clinician-scientists trained in clinical and translational cancer research, and to promote their career development as cancer researchers. This Funding Opportunity Announcement (FOA) allows appointment of Scholars proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary study to an existing trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.

The purpose of this notice of funding opportunity (NOFO) is to solicit applications proposing innovative transdisciplinary research that integrates approaches across social/cognitive neuroscience and other social sciences and will lead to a testable conceptual or computational model that provides mechanistic insights into social behavior and its relationships with the onset, trajectory and impact of Substance Use Disorders (SUD) and comorbidities. This NOFO is specifically soliciting applications proposing BESH research, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Application budgets are not limited but need to reflect the actual needs of the proposed project.

The "Short Courses on Utilizing the NIH Stage Model to Develop Behavioral Interventions to Promote Healthy Aging" grant aims to fund the creation of short educational programs that teach researchers how to use the NIH Stage Model to develop non-drug interventions that encourage healthy aging and improve care for older adults.